1032903-52-8

Basic information

• Product Name: 4-(2-methyl-4-nitro-5-isopropoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester
• Synonyms: 4-(2-methyl-4-nitro-5-isopropoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester
• CAS NO: 1032903-52-8
• Molecular Weight: 376.453
• Mol File: 1032903-52-8.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 4-(2-methyl-4-nitro-5-isopropoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-methyl-4-nitro-5-isopropoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester(1032903-52-8)
• EPA Substance Registry System: 4-(2-methyl-4-nitro-5-isopropoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester(1032903-52-8)

Safety Data

• Hazardous Substances Data: 1032903-52-8(Hazardous Substances Data)

Upstream product

• 1032903-51-7 2-(5-isopropoxy-2-methyl-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxide cyclopentaborane 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1032903-50-6 1-chloro-2-methyl-4-nitro-5-(propan-2-yloxy)benzene 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 452-73-3 2-chloro-4-fluorotoluene 
• 112108-73-3 1-chloro-5-fluoro-2-methyl-4-nitrobenzene 
• 67-63-0 isopropyl alcohol 
• 64695-96-1 1-bromo-5-fluoro-2-methyl-4-nitrobenzene 
• 1202858-68-1 1-bromo-5-isopropoxy-2-methyl-4-nitrobenzene 

Downstream Products

• 1190399-91-7 5-chloro-N²-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N⁴-[2-(isopropylsulfonyl)phenyl]pyrimidine-2,4-diamine dihydrochloride 
• 1035230-24-0 5-chloro-N²-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N⁴-((2-isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 1380575-43-8 5-chloro-N²-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine hydrochloride 
• 1032900-25-6 5-chloro-N²-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N⁴-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine 
• 1032903-64-2 4-(4-{5-chloro-4-[2-(propane-2-sulfonyl)phenylamino]pyrimidin-2-ylamino}-5-isopropoxy-2-methylphenyl)piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROS1 INHIBITOR AND EGFR INHIBITOR

Provided herein is a method for treating or suppressing a cancer, reducing its severity, lowering its risk or inhibiting its metastasis in an individual. The method comprises administering to the individual a therapeutically effective amount of one or more of a FAK inhibitor, an ALK inhibitor and a ROS1 inhibitor, and a therapeutically effective amount of an EGFR inhibitor. Provided herein is also a pharmaceutical composition or kit comprising one or more of a FAK inhibitor, an ALK inhibitor and a ROS 1 inhibitor, and an EGFR inhibitor.

Anaplastic lymphoma kinase (ALK) inhibitor, and preparation method and application thereof

The invention relates to a compound as shown in a formula (I) which is described in the specification, and a pharmaceutical composition and a preparation method thereof. The compound can be used as anALK inhibitor for treatment of diseases mediated by ALK. The invention further relates to application of the compound as shown in the formula (I) and the pharmaceutical composition thereof to preparation of drugs used for treating diseases mediated by ALK.

CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF

Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.